Stock Ratings / Health Care / CCEL / options

PARK (60) NIVF (20) MGRX (28) VMD (72) ⌘ Pro Terminal →

Cryo-Cell International Inc. (CCEL) Options Positioning, Max Pain & Unusual Sweeps

$5.21 +0.48% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.23

Cryo-Cell International Inc. (CCEL) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (steady margins, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate) →

ROARABLE B- • BUY Cap $42.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CCEL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cryo-Cell International Inc. (NYSE: CCEL) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $5.21 (+0.48% 1D, market cap $42.0M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, CCEL ranks #80 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CCEL compare to PARK and NIVF in the Health Care sector?

▼

Within the Health Care sector (Misc Health and Biotechnology Services), CCEL carries a Roarable B- (70/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 18.2%. By comparison, PARK (Park Dental Partners Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $100.3M) and NIVF (NewGenIvf Group Limited (Class A)) posts a E grade (20/100 RQD, P/E N/A, ROIC -32.8%, cap $9.7M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CCEL?

▼

Per CCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-11-30, CIK 0000862692), Cryo-Cell International Inc. generated $0 in revenue, -$2.4M in net income, and $5.2M in free cash flow against $61.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.23 (+0.33%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CCEL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (70/100 Composite)

🔍 WHY CCEL SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($5.2M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (21% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk10/20 pts (-10 pt drag)

Balance-sheet & 10-K footnote risk deducts 10 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$4.30+10.5% Next Q

Q2 (-2Q)

Grade C+$4.75+4.4% Next Q

Q3 (-1Q)

Grade B-$4.96+5% Next Q

Current

Grade B-$5.21+6.6% Hist 90D α

Trajectory: C+ (62) → B- (70)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CCEL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 70/100 (B-) score, CCEL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.34) or 200D SMA ($3.70) invalidates the momentum regime and cuts Target Base ($5.49) toward Bear Floor ($4.27).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CCEL Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”

YES 70%NO 30%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CCEL)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CCEL.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating CCEL & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on CCEL
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +48.43%▲ ASCENDING CHANNEL

2026-11-03O $5.18H $5.21L $5.18C $5.21VOL 12.1K

RES: $5.48SUP: $3.57SMA50: $4.34SMA200: $3.70

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CCEL Butterfly Map → + Track CCEL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CCEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CCEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CCEL)

Health Care Rank #80 of 1016 ⚔️ PARK vs CCEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CCEL vs. PARK, NIVF, MGRX, VMD)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cryo-Cell International Inc. (CCEL) ranks #80 by composite RQD confidence (70/100, grade B-) and #766 by equity capitalization ($42.0M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. VMD currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with CCEL at 70/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CCEL ACTIVE Cryo-Cell International Inc.	B-	70/100	—	—	18.2%	+0.48%	$42.0M	Benchmark Subject
PARK Park Dental Partners Inc.	C-	60/100	—	—	—	+5.14%	$100.3M	/park-vs-ccel →
NIVF NewGenIvf Group Limited (Class A)	E	20/100	—	—	-32.8%	-14.05%	$9.7M	/nivf-vs-ccel →
MGRX Mangoceuticals Inc.	E	28/100	—	54.9%	-35.0%	-8.22%	$5.2M	/mgrx-vs-ccel →
VMD Viemed Healthcare Inc.	B	72/100	24.6x	57.5%	13.0%	-2.81%	$368.3M	/vmd-vs-ccel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-11-30 • CIK 0000862692

In its most recent audited fiscal period (FY2025, filed 2025-11-30), Cryo-Cell International Inc. (CCEL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$2.4M, operating cash flow of $5.5M, and free cash flow of $5.2M (+45.5% YoY). On the balance sheet, CCEL closed FY2025 with $61.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-11-30	$0	-$2.4M	$5.5M	$5.2M	$61.7M	—
FY2024 (FY)	2024-11-30	$0	$402.0K	$6.0M	$3.6M	$64.7M	—
FY2023 (FY)	2023-11-30	$0	-$9.5M	$8.9M	$8.9M	—	—

3. CCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CCEL compare to PARK and NIVF in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CCEL?

Where is CCEL trading relative to its 50-day, 200-day, and 52-week technical levels?

CCEL last traded at $5.21 (+0.48% on volume of 12,051 shares), positioning the stock +20.05% above its 50-day simple moving average ($4.34) and +40.81% above its 200-day simple moving average ($3.70). Across its 52-week range of $2.72 to $5.45, CCEL sits at the 91.2% percentile with a 14-day RSI of 64.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.56 to $5.86).

CCEL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CCEL's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CCEL.

Direct Sub-Reports: CCEL RQD Cockpit CCEL 12M Forecast CCEL Earnings & Move CCEL Dividends & DRIP CCEL Insiders & 13F CCEL Whale Options CCEL Profit Sankey CCEL News & Why

ROARABLE RATING BRIEF • RQD 70/100 (B-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CCEL — Cryo-Cell International Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:47:32Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns CCEL a score of 70, a letter grade of B-, and the verdict "Roarable Buy — Sound Institutional Accumulation" (per the Roarable RQD rating). The five pillars break down as follows:

Fundamental Cash Engine: 17 / 20. This is the strongest pillar. The source cites ROIC of 18.2% and an FCF yield of 12.55% (per the Roarable RQD rating and Market Data). For a prospective investor, this suggests the business generates meaningful returns on invested capital and substantial free cash flow relative to its market value, which is the core of the upside case. The tradeoff is that the reported net margin is 0% and reported revenue is shown as $0.0M in each period, so the cash-generation thesis rests on figures that the reported income statement does not fully corroborate.
Whale / 13F Flow: 15 / 20. The rating describes institutional accumulation and options positioning as a positive signal (per the Roarable RQD rating). However, the Holders section contains no 13F data, so this pillar cannot be independently verified from the source data supplied.
Insider Conviction: 13 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow (per the Roarable RQD rating). The news wire does reference a director receiving stock options (per the Recent Catalysts section), which is a modest, verifiable insider-alignment data point, but the cluster-flow detail itself is not in the source data.
Macro Regime Fit: 15 / 20. Beta is 1.0 (per Market Data), meaning the source characterizes the stock as moving in line with the broader market. The pillar indicates reasonable sector-sensitivity compatibility, but no macro-regime data beyond beta is provided.
Forensic Balance Sheet: 10 / 20. This is the weakest pillar. The rating cites an Altman Z of 2.5, a Piotroski F of 3/9, and Debt/Equity of 0.5 (per the Roarable RQD rating). A Piotroski F of 3 out of 9 is a weak reading on the source's own scale, and the balance sheet cannot be fully confirmed because cash and debt values are partly reported as N/A in the SEC financials. A prospective investor should weigh this pillar as the principal caution.

Overall, the rating's profile is one of strong cash-return metrics paired with a weaker forensic balance-sheet pillar and thin reported profitability. The tradeoff is that the valuation signal (EV/EBITDA of 61.2 per Market Data) is elevated, so upside depends on the cash-generation metrics holding up against an already-demanding enterprise-value multiple.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$0.5M	$-2.4M	N/A	$5.2M	$0.3M	N/A
FY 2024	$0.0M	$3.5M	$0.4M	N/A	$3.6M	$0.6M	N/A
FY 2023	$0.0M	$-12.3M	$-9.5M	N/A	$8.9M	N/A	N/A

Reported operating income was positive in FY 2025 ($0.5M) and FY 2024 ($3.5M) after a loss in FY 2023 ($-12.3M), while net income was negative in FY 2025 ($-2.4M) and FY 2023 ($-9.5M) and positive in FY 2024 ($0.4M). Reported margins are 0% across gross, operating, and net measures (per Market Data), and ROIC is 18.2% (per Market Data). The Roarable RQD rating cites an Altman Z-Score of 2.5 and a Piotroski F-Score of 3/9 (per the Roarable RQD rating). The balance sheet shows Debt/Equity of 0.5 (per the Roarable RQD rating), while reported cash is $0.3M in FY 2025 and $0.6M in FY 2024, with cash and debt partly N/A in the SEC financials.

Open Questions

What drives the reported ROIC of 18.2% and FCF yield of 12.55% when reported revenue is $0.0M and net margin is 0%?
What are CCEL's cash and debt balances in the periods where the SEC financials show N/A?
What is the basis for the 7.73% dividend yield, and is it supported by reported cash flows?
What specific products, customers, or revenue sources generate the company's cash flow?
What do the 13F and Congressional PTR flows referenced in the RQD pillars actually show, given that the Holders section is empty?

CCEL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cryo-Cell International Inc. (CCEL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CCEL Debate Forum (3) ↓

🟡 MARKET WIRE Stock Titan • 18h ago

A director receives 5,300 Cryo-Cell (CCEL) stock options with a $4.96 exercise price.

Stock Titan report covering Cryo-Cell International Inc. (CCEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 21h ago

Goodyear Tire, Cryo-Cell International and 3 Stocks to Watch Heading Into Monday

Benzinga report covering Cryo-Cell International Inc. (CCEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Shareholders ratify WIPFLI with 7.58M votes at Cryo-Cell (CCEL)'s annual meeting.

Stock Titan report covering Cryo-Cell International Inc. (CCEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 17d ago

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics (NASDAQ:TCRT)

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 24d ago

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results

OLDSMAR, Fla., October 09, 2026--Cryo-Cell International, Inc. (NYSE American, Symbol: CCEL) (the "Company", "Cryo-Cell"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced res

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 110d ago

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results

OLDSMAR, Fla., July 15, 2026--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 6d ago

CCEL 8-K & SEC Filings

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9xV2xJR1VESUt1WEk4U01rN2JRQ1hNdjFBZG9JTVB4UFlkS2htMUl5RG93Z25TNUJzZkZWbXdQeGVsb3VWYjBtSXRldmR5aG1jQ2xrZ0lHZFE5azEtd3FfTXlINXhtZl9QZ3JTQlFWbkhnLVVVNmY3Yg?oc=5

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 18d ago

12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos Th

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNS3VQaFBwZngyUFYtZUhYN2Uwb0tDSW9GMUo0QUZFS3VCaHlob1hXQ1RyU1VoaFZuaEZsTGVjQXJfSWpxdHpFQ2RiZkRMUUpqSjdibkdMQi1CZTdyOXNSSmp2V3pObXRreTR5U3J2RC1yMXlwbXA0OVBINXN

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CCEL Bull vs. Bear Conversation Board — What's Your Call at $5.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CCEL 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $6.12 (+17.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CCEL (B- • RQD 70/100) a Buy at $5.19?

Welcome to the CCEL (Cryo-Cell International Inc.) Roar Pit. Current RQD Composite is 70/100 (Roarable Buy — Sound Institutional Accumulation) in Misc Health and Biotechnology Services. Bulls point to capital efficiency (18.2% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.89 (-25.0%)

Spot @ $5.19

Pump the brakes on CCEL — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CCEL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cryo-Cell International Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.12 (+17.9%)

Spot @ $5.19

CCEL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CCEL, the market is fixating on short-term headline noise in Misc Health and Biotechnology Services and ignoring the balance sheet and cash flow trajectory. At $5.19 (52-wk range $2.72 - $5.45), any beat on forward guidance forces shorts and underweight funds to chase.